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Sir, 
Diagnosis of drug-induced liver injury (DILI) due to herbal and dietary supplements (HDS) is 
notoriously difficult and often based on circumstantial evidence and exclusion of other 
causes. Risk factors are poorly defined and the spectrum of potential culprit products is 
changing continuously. Among the well-known precipitators of acute liver injury potentially 
causing liver failure are products derived from Kava (Piper methysticum rhizoma) previously 
used for the treatment of anxiety and depression. Over 100 cases of serious liver damage 
have been recorded worldwide, with numerous Kava products from different manufacturers 
and no obvious pattern with regard to mode of extraction, dosage, duration of intake, co-
medication or patient characteristics. Following numerous cases of fulminant liver failure 
leading to liver transplantation and death, Kava products were banned in the United States, 
Europe and Australia (1). Although clinical presentation was considerably variable, causality 
assessment left little doubt that Kava was the cause in a majority of a series of 29 cases of 
adverse hepatic reactions due to Kava in Germany (2). Among these patients, nine 
developed fulminant liver failure with subsequent liver transplantation in eight of the 
patients, and three died eventually. Apart from the fact that the majority of individuals were 
women, likely reflecting consumers’ preferences rather than true disposition, no apparent 
risk factor could be identified. Russmann and coworkers suggested a poor-metabolizer 
phenotype of cytochrome P450 2D6 as a risk factor for developing Kava-related liver damage 
(3), however, this observation is has not made it into routine diagnostics to identify subjects 
at risk.  
In this issue of the Archives, Aghdassi et al. present an interesting suggestion that there may 
be a possible additional degradation pathway, and genetic risk factor for Kava-related DILI 
related to the degradation of kavapyrones by a variation of the gene coding for uridine-
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diphosphate (UDP)-glucuronosyltransferase, UGT1A7*3 (4). Authors genotyped 4 patients 
with fulminant hepatic failure following kava ingestion and found an UGT1A7*3 allele 
frequency of 37.5%, and 50% in those undergoing liver transplantation, but no CYP2D6 poor 
metabolizer phenotype. Considering the UGT1A7*3 allele frequencies among Caucasians 
between 16-36%, authors felt that the mild overrepresentation in their patients could be a 
hint for UGT1A7*3 as a genetic risk factor. In earlier studies, variant UGT1A7*3 was found in 
43 of 59 patients with hepatocellular carcinoma studied by Vogel and co-workers (5), but 
this finding was later revised and attenuated after re-genotyping an enlarged cohort 
unravelled a PCR amplification bias (6). Although the idea is intriguing, several aspects call 
for caution in this regard: 1. With such low numbers, the presented series of 4 (!) patients 
may well be subject to a type I error detecting an association that does not exist; frankly 
speaking, the UGT1A7*3 allele frequency of 50% in transplant liver recipients may simply be 
a chance finding, and more patients need to be genotyped to generate robust data that 
withstand statistical scrutiny. For this, it would be interesting to see the UGT1A7*3 allele 
frequency in a larger series of patients with unequivocal kava-related liver injury, and 
networking with data bases maintained by international DILI networks is encouraged to find 
such patients (7, 8); 2. The UGT1A7 isoenzyme is not expressed in the liver, which renders its 
importance for liver-related idiosyncratic drug reactions rather low, although it was 
suggested that may function as a gatekeeper for xenobiotics at their first entry into the 
human body; 3. Among the mutations in the UGT gene with a high prevalence in the 
population is that coding for Gilbert-Meulengracht hyperbilirubinemia, commonly not 
associated with DILI, but other misadventures. For example, genetic polymorphisms in 
UGT1A1, such as UGT1A1*28 in Caucasians and Asians and UGT1A1*6 only in Asians modify 
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the tolerability of irinotecan, resulting in severe neutropenia in homozygous carriers of one 
or heterozygosity of either variation (9).  
In conclusion, there seems to be yet inconclusive evidence that genetic variations in the UGT 
gene have a significant share in the predisposition to Kava-related DILI until there is more 
supportive data. But there may be other genetic variants with a more significant impact, and 
efforts to their identification are clearly commendable.  
And although Kava is thankfully off the market, other products are on the rise with unclear 
risk profiles and the potential to cause life-threatening liver injury (10). Attentive 
surveillance of their use remains an important task, and thrusting work-up of cases is 
warranted should toxicities occur. 
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